Natco, Other Generics Ask U.S. High Court To Lift Stay On Copaxone Sales
This article was originally published in PharmAsia News
India's Natco Pharma and global makers of generic drugs filed a formal petition with the U.S. Supreme Court to lift an injunction against them pending the outcome of a patent dispute with Israel's Teva Pharmaceutical Industries.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.